EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients

A Patient Registry Collecting the Clinical and Molecular Profiling Data of Patients With Locally Advanced and/or Metastatic, Unresectable, Stages IIIB/C or IV Non-small Cell Lung Cancer (NSCLC), Who Have Not Previously Been Treated for This Advanced Disease and Are Therefore Considered as Patients Receiving First-line Therapy.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07096258

Acronym

EMPATHY NSCLC

Enrollment

1000

Registered

2025-07-31

Start date

2024-06-01

Completion date

2031-12-31

Last updated

2025-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Brief summary

The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer (NSCLC). The main objective of the study is to better understand the real-world clinical practice of the use and utility of molecular tumour profiling, the choice of treatment, and the outcome after such molecular profiling and treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Locally advanced or metastatic, unresectable NSCLC, stages IIIB/C or IV, who have not previously been treated for this advanced disease. * Intention-to-initiate first-line tumour therapy for this advanced disease. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2. * At least 18 years of age on the day of signing informed consent, and capable of signing informed consent.

Exclusion criteria

* Any known non-cutaneous malignancy (except for this NSCLC and early-stage non-invasive cervical cancer) that has occurred within 5 years prior to enrolment.

Design outcomes

Primary

Measure	Time frame	Description
Actionable biomarkers	At baseline	Proportion of patients with successful molecular profiling and detectable actionable biomarkers

Countries

France, Italy, Spain, Switzerland

Contacts

Primary ContactDr. Christian Meisel, MD PhD

HederaDxStudies@hederadx.com+41 21 588 16 54

Outcome results